

CONTENTS

EXECUTIVE SUMMARY	1
I. INTRODUCTION	5
1.1. Background	5
1.2. Objectives	6
1.3. Scope	7
1.4. Structure	7
2. BACKGROUND INFORMATION	8
2.1. The site	8
2.2. Relevant organizations and radiological protection infrastructure in Georgia	8
2.2. 1. Regulatory authority	8
2.2.2. Relevant organizations	10
3. CHRONOLOGY OF THE ACCIDENT	11
4. RECOVERY OF SOURCES	13
4.1. Radiological monitoring at the Lilo facility	13
4.2. Radiological survey	13
4.3. Determination of the radionuclide involved	16
4.4. Storage facility	18
4.5. Physical protection of the sources	18
5. CO-OPERATION BETWEEN THE WHO AND THE IAEA	19
6. IAEA MISSION	20
6.1. Objectives of the mission	20
6.2. Radiological survey equipment	21
6.3. Radiological survey results	21
6.4. Soil sample measurements	24
7. BIOLOGICAL DOSIMETRY	24

7.1.	Cytogenetic investigations	24
7.2.	Electron spin resonance dosimetry	27
7.3.	Monte Carlo method of dose reconstruction	27
8.	OVERVIEW OF THE MEDICAL ASPECTS	30
9.	PRIMARY MEDICAL ASSESSMENT OF THE PATIENTS BY LOCAL PHYSICIANS IN GEORGIA ,	31
9.1.	Period prior to hospitalization	31
9.2.	Diagnosis and treatment in hospitals in Georgia	31
9.2.1.	General clinical manifestations and management of patients	31
9.2.2.	Cutaneous signs and symptoms	34
9.2.3.	Haematological indices	39
9.2.4.	Chromosomal analysis	39
9.2.5.	Immunological status	41
9.2.6.	Results of microbiological investigations	41
9.2.7.	Functional status of physiological systems	41
9.2.8.	Treatment provided in Georgia	42
10.	DIAGNOSIS AND TREATMENT IN SPECIALIZED HOSPITALS IN FRANCE AND GERMANY	42
10.1.	Overview	42
10.2.	Cutaneous syndrome	43
10.2.1.	Initial medical check-up	43
10.2.2.	Cutaneous signs and symptoms	44
10.2.3.	MRI results	45
10.2.4.	Telethermography results	45
10.2.5.	20 MHz ultrasound results	45
10.2.6.	X ray results	45
10.2.7.	Bacteriological results	49
10.2.8.	Treatment of the cutaneous syndrome	49
10.2.9.	Outcome of the treatment	52
10.3.	Haematological data	56
10.4.	Reproductive system	60
10.5.	Other organs and organ systems	64
105.1.	Cardiovascular system	64
105.2.	Liver	64
105.3.	Respiratory system	64

10.5.4. Thyroid	64
10.5.5. Additional examinations by specialists	65
10.6. Special case histories	65
I I. PATHOPHYSIOLOGICAL CONSIDERATIONS REGARDING THE DEVELOPMENT OF CLINICAL SIGNS AND SYMPTOMS	76
12. TREATMENT OF FOUR PATIENTS WITH RECURRENT SKIN ULCERS IN A SPECIALIZED HOSPITAL IN THE RUSSIAN FEDERATION	79
13. CONCLUSIONS DRAWN FROM THE MEDICAL MANAGEMENT OF THE PATIENTS	82
14. RECOMMENDATIONS ON THE FOLLOW-UP OF THE PATIENTS	83
15. CONCLUSIONS AND LESSONS TO BE LEARNED	84
15.1. Conclusions	84
15.2. Lessons to be learned	86
ANNEX I: STATUS OF THE GEORGIAN PATIENTS IN AUGUST 1999	91
ANNEX II: WHO COLLABORATING CENTRES AND LIAISON INSTITUTIONS WITHIN REMPAN	93
REFERENCES	97
ABBREVIATIONS	99
CONTRIBUTORS TO DRAFTING AND REVIEW	101